Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Stanley Frankel, MD Medical Monitor
Precision BioSciences, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Queen Mary Hospital, the University of Hong Kong
Hong Kong, Hong Kong, Hong Kong
Recruiting
- Ics Arensia Exploratory Medicine Srl
Chisinau, Moldova
Recruiting
- New Zealand Clinical Research
Auckland, New Zealand
Recruiting
- Massachusetts General Hospital/harvard University
Boston, Massachusetts, United States
Raymond T Chung, MDRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 14 Nov 2024
- Primary completion
- 31 Dec 2025
- Completion
- 31 Dec 2026
- Last update posted
- 26 Sept 2025
- Registered enrollment
- 45
- Registry id
- NCT06680232
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.